Articles tagged "HLA antibodies"

2021 American Transplant Congress
Relationship Between %dd-cfDNA, MMDx Molecular Diagnoses, and Donor-specific Antibody in the Trifecta Study
P. F. Halloran¹, L. G. Hildago², J. Reeve¹, Z. Demko³, A. Prewett³, P. Billings³, J. Truong⁴, P. Vander Horn⁴, &. Trifecta Study Group⁵
¹Alberta Transplant Applied Genomics Centre, Edmonton, AB, Canada, ²University of Wisconsin, Madison, WI, ³Natera Inc., San Carlos, CA, ⁴One Lambda Inc., West Hills, CA, ⁵., ., AB, Canada
*Purpose: The Trifecta Study is a prospective multicenter investigator-initiated trial to evaluate the relationship between %dd-cfDNA and molecular biopsy findings at the time an indication…
2021 American Transplant Congress
Higher Calcineurin Inhibitor Levels Associate with Graft Outcomes in Kidney Recipients with De Novo Donor-specific Antibodies of Either Hla Class I or II
M. Béland, S. De Serres
Nephrology, CHU de Québec- Université Laval, Québec, QC, Canada
*Purpose: The development of de novo anti-HLA donor specific antibodies (dnDSA) is associated with poorer outcomes in kidney transplant recipients. We and other previously reported…
2021 American Transplant Congress
Athena – Effect of Primary Immunosuppression on Development of De Novo Donor Specific Antibodies within First Year After Kidney Transplantation
W. Arns¹, A. Philippe¹, V. Ditt¹, I. A. Hauser¹, F. Thaiss¹, C. Sommerer¹, B. Suwelack¹, A. Finkel², C. Schiedel², D. Dragun¹, B. Nashan¹
¹ATHENA, Study Group, Germany, ²Novartis Pharma GmbH, Nuremberg, Germany
*Purpose: The ATHENA trial [NCT01843348] investigated safety and efficacy of everolimus combined with cyclosporine A [EVR/CsA] or tacrolimus [EVR/TAC] vs. tacrolimus plus mycophenolic acid [MPA/TAC]…
2021 American Transplant Congress
Non-HLA Antibodies and Eplet Mismatches in Cases with Histological Picture of Antibody-Mediated Rejection with and without HLA Donor-Specific Antibodies
M. Crespo¹, L. Llinás², D. Redondo², C. Butler³, J. Gimeno⁴, M. Pérez-Sáez², A. Buxeda², C. Arias², M. Folgueiras², S. Sanz², N. Valenzuela³, E. E. Reed³, J. Pascual²
¹Nephrology and Kidney Transplantation, Hospital del Mar, Barcelona, Spain, ²Nephrology, Hospital del Mar, Barcelona, Spain, ³UCLA Immunogenetics Center, UCLA, Los Angeles, CA, ⁴Pathology, Hospital del Mar, Barcelona, Spain
*Purpose: Correlation between antibody-mediated rejection (ABMR) and HLA donor-specific antibodies (DSA) is strong but imperfect in kidney transplant (KT) recipients, raising the possibility of other…
2021 American Transplant Congress
Lung Transplant Recipients Developing Early DSAs are Characterized by a Shift Towards Memory B Cells Directly After Transplantation
S. Christoph¹, A. Hitz¹, R. Bellmàs Sanz¹, J. Kühne¹, B. Wiegmann², F. Ius², J. Salman², E. Chichelnitskiy¹, T. Siemeni², W. Sommer³, A. Haverich², G. Warnecke³, C. Falk¹
¹Institute of Transplant Immunology, MHH, Hannover, Germany, ²Department of Cardiothoracic, Transplant and Vascular Surgery, MHH, Hannover, Germany, ³Department of Cardiac Surgery, University Hospital Heidelberg, Heidelberg, Germany
*Purpose: After lung transplantation (LTx), the development of early donor HLA-specific antibodies (eDSA) is associated with antibody-mediated rejection (AMR) and poor graft survival. Since 2013,…
2021 American Transplant Congress
The Importance of Persistent and Recurrent T Cell Mediated Rejection in Tacrolimus Treated Renal Transplant Recipients
C. Rampersad¹, I. W. Gibson², D. N. Rush¹, D. Pochinco³, P. E. Birk⁴, A. Goldberg⁴, T. Blydt-Hansen⁵, M. Karpinski¹, J. Shaw¹, J. Ho¹, P. W. Nickerson¹, C. Wiebe¹
¹Department of Medicine, University of Manitoba, Winnipeg, MB, Canada, ²Department of Pathology, University of Manitoba, Winnipeg, MB, Canada, ³Shared Health Services Manitoba, Winnipeg, MB, Canada, ⁴Department of Pediatrics and Child Health, University of Manitoba, Winnipeg, MB, Canada, ⁵Department of Pediatrics, University of British Columbia, Winnipeg, MB, Canada
*Purpose: Optimal follow-up after treatment for T-cell mediated rejection (TCMR) is not well-established. We sought to identify the prevalence and clinical associations of repeated TCMR…
2021 American Transplant Congress
Utility of Screening-Bead Assay in Post-Transplant Testing of Donor-Specific Antibodies (DSA) and Antibody-mediated Rejection (ABMR) in Renal Allografts
A. Agrawal¹, E. Dijke², A. Murray³, P. Campbell³
¹Transplant Nephrology, Mayo Clinic, Rochester, MN, ²Lab. Medicine and Pathology, University of Alberta Hospital, Edmonton, AB, Canada, ³Division of Nephrology, Dept. of Medicine, University of Alberta Hospital, Edmonton, AB, Canada
*Purpose: ABMR is a major cause of poor long-term graft survival. Though post-transplant monitoring of HLA DSAs can aid in risk stratification and optimizing immunosuppression,…
2021 American Transplant Congress
Antibodies to Hla Molecules Lead to Induction and Release of Circulating Exosomes with Lung Self-Antigens
R. Ravichandran, M. Smith, R. Bremner, T. Mohanakumar
St. Joseph’s Hospital and Medical Center, Phoenix, AZ
*Purpose: Antibodies (Abs) to human leukocyte antigen (HLA) (anti-HLA) can injure allograft by complement-dependent/independent mechanisms. Crosslinking of HLA-class I with Abs associate with integrin β4…
2021 American Transplant Congress
Dynamics of IgG Subclass as a Mechanism of Desensitization Using Rituximab for Presensitized Patients Undergoing Living Related Liver Transplantation
H. Egawa¹, K. Ide², T. Ishizuka³, H. Ohdan⁴, Y. Kotera¹, T. Kato¹, A. Ohmori¹, Y. Hirata¹, G. Shibuya¹, S. Yamashita¹, S. Ariizumi¹
¹Tokyo Women's Medical University, Tokyo, Japan, ²Surgery, Hiroshima University, Hiroshima, Japan, ³Clinical Laboratory, Tokyo Women's Medical University, Tokyo, Japan, ⁴Hiroshima University, Hiroshima, Japan
*Purpose: Although impact of preformed HLA-related donor specific antibody (DSA) and necessity of desensitization in liver transplantation (LT) has been recognized, mechanisms of desensitization in…
2020 American Transplant Congress
Analysis of 1000 Protocol Kidney Biopsies: Complications, Benefits, and Predictive Potential of Prior Sensitization
M. Eslami¹, J. Patel², S. Karzai¹, D. T. Collins¹, C. Liu¹, J. Jonsson¹, R. Wali¹, J. B. Piper¹
¹Surgery, Inova Fairfax Hospital, Falls Church, VA, ²General Surgery, Pennsylvania State University, State College, PA
*Purpose: Protocol biopsy of kidney transplants can allow for early recognition of treatable findings, both immunologic and non-immunologic. This comes with the risk of biopsy…

« Previous Page
1
…
5
6
7
8
9
…
47
Next Page »